Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Clin Cancer Res. 2022 Mar 1;28(5):972–983. doi: 10.1158/1078-0432.CCR-21-2949

Fig. 1. Heterogeneity and prognostic effects of MYC/BCL2 expression in DLBCL genetic subsets.

Fig. 1

(A) Combined MCD and BN2 cases compared with combined EZB, ST2, A53, and ‘Other’ subtype cases had significantly higher MYC expression evaluated by immunohistochemistry (IHC). Combined EZB, MCD, BN2, and A53 cases compared with combined ST2 and ‘Other’ subtype cases had significantly higher BCL2 expression. Each dot represents one patient. P values are 2-tailed (unpaired t and Mann-Whitney) and exact (Mann-Whitney). (B) MYC/BCL2 double-high-expression (DhE) and MYC/BCL2 genetic double-hit (DH) had significant adverse impact on overall survival (OS) in the EZB genetic subtype. Single MYChi (without concurrent BCL2hi) expression did not have significant prognostic effect in EZB. (C) DhE and high MYC expression were associated with significantly poorer progression-free survival (PFS) in the BN2 genetic subset. (D) Heatmaps for significantly differentially expressed genes between DhE and non-DhE cases in the EZB subset and between EZB and non-EZB cases in the DhE subgroup. (E) Representative Uniform Manifold Approximation and Projection (UMAP) plots generated from single-cell intensities for CD20, CD3, CD68, CD56, PD-1, and PD-L1 markers in three EZB cases with non-DhE, DhE, and MYC/BCL2-DH, respectively. Each datapoint represents a cell, labeled according to phenotype. In the legends, PD-L1/PD-1-negative phenotypes in CD20+, CD3+, CD56+, and CD68+ were omitted.